The INSIGHT study: A randomized, phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Researchers in the INTRIGUE trial found that ripretinib, which targets KIT mutations, showed promise over sunitinib in advanced gastrointestinal stromal tumors (GIST) with specific mutations. The Phase III INSIGHT study evaluated ripretinib versus sunitinib in advanced GIST patients with KIT exon 11 + 17/18 mutations, identified through ctDNA analysis. The trial aimed to confirm ripretinib’s efficacy in progression-free survival and explore ctDNA as a predictive biomarker for personalized second-line therapies in advanced GIST.